Elpis Biomed's Dr Mark Kotter spoke to Proactive London's Andrew Scott after being voted the 2018 Cambridge Start-Up of the Year.
Elpis is developing high quality human cells via its proprietary OPTi-OX platform.
Kotter also discusses their fundraise which they're in the middle of. He says he's looking to raise up to £5mln and is keen to expand the investor portfolio.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of bit bio named herein, including the promotion by the Company of bit bio in any Content on the Site, the Company receives from said issuer...
FOR OUR FULL DISCLAIMER CLICK HERE